NVST
NVST
Envista Holdings CorpIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $705.5M ▼ | $327.6M ▼ | $38.7M ▲ | 5.49% ▲ | $0.24 ▲ | $62.5M ▼ |
| Q4-2025 | $750.6M ▲ | $337.3M ▲ | $32.9M ▲ | 4.38% ▲ | $0.2 ▲ | $104.9M ▲ |
| Q3-2025 | $669.9M ▼ | $310.3M ▼ | $-30.3M ▼ | -4.52% ▼ | $-0.18 ▼ | $94M ▲ |
| Q2-2025 | $682.1M ▲ | $319.4M ▲ | $26.4M ▲ | 3.87% ▲ | $0.16 ▲ | $80.6M ▲ |
| Q1-2025 | $616.9M | $297M | $18M | 2.92% | $0.1 | $74.6M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $1.08B ▼ | $5.58B ▼ | $2.5B ▼ | $3.08B ▼ |
| Q4-2025 | $1.21B ▲ | $5.68B ▲ | $2.57B ▲ | $3.11B ▲ |
| Q3-2025 | $1.13B ▲ | $5.64B ▼ | $2.55B ▲ | $3.09B ▼ |
| Q2-2025 | $1.11B ▲ | $5.66B ▲ | $2.53B ▲ | $3.14B ▲ |
| Q1-2025 | $1.08B | $5.47B | $2.43B | $3.04B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $38.7M ▲ | $-3.3M ▼ | $-68.9M ▼ | $-45.6M ▼ | $-128.9M ▼ | $-15.8M ▼ |
| Q4-2025 | $32.9M ▲ | $108M ▲ | $-15.5M ▼ | $-25.2M ▲ | $77.8M ▲ | $91.7M ▲ |
| Q3-2025 | $-30.3M ▼ | $78.7M ▼ | $-9.7M ▲ | $-41.7M ▲ | $23.3M ▼ | $67.9M ▼ |
| Q2-2025 | $26.4M ▲ | $88.7M ▲ | $-17.1M ▼ | $-86.4M ▼ | $33.3M ▲ | $76.4M ▲ |
| Q1-2025 | $18M | $300K | $-8.8M | $-17.6M | $8.2M | $-5.6M |
Revenue by Products
| Product | Q3-2023 | Q4-2023 | Q1-2024 | Q4-2024 |
|---|---|---|---|---|
Equipment and Consumables | $230.00M ▲ | $450.00M ▲ | $210.00M ▼ | $680.00M ▲ |
Specialty Products and Technologies | $400.00M ▲ | $830.00M ▲ | $410.00M ▼ | $1.21Bn ▲ |
Revenue by Geography
| Region | Q2-2025 | Q3-2025 | Q1-2026 |
|---|---|---|---|
North America | $350.00M ▲ | $350.00M ▲ | $360.00M ▲ |
Western Europe | $150.00M ▲ | $140.00M ▼ | $180.00M ▲ |
Q1 2026 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Envista Holdings Corp's financial evolution and strategic trajectory over the past five years.
Key strengths include a resilient and gradually growing revenue base, strong and stable gross margins, and consistently positive operating and free cash flow. The company also benefits from a broad, trusted brand portfolio, a large installed base in dental practices worldwide, and a clear strategic focus on digital and AI‑enabled solutions. Improved liquidity and reduced net debt add financial flexibility on top of these operating advantages.
Major risks center on profitability volatility and capital erosion. Significant losses and write‑downs in recent years have pushed retained earnings negative and reduced equity, even as revenue has inched higher. Rising overhead costs, intense competition in core product lines, and the need for ongoing investment in innovation all create pressure on margins and returns. Execution missteps in large initiatives—such as clear aligners or digital platforms—could further weigh on financial performance.
The overall picture is of a company with solid market positioning and cash‑generation capabilities that is working through the financial aftereffects of past charges, elevated costs, and portfolio adjustments. If Envista can stabilize margins, better align expenses with its growth pace, and successfully monetize its digital and AI investments, its financial profile could gradually move back toward the stronger levels seen earlier in the period. At the same time, the combination of competitive intensity and a still‑scarred equity base means future results may remain uneven, and progress will likely be measured more in steady operational improvements than in rapid transformation.
About Envista Holdings Corp
http://www.envistaco.comEnvista Holdings Corp. manufactures and markets dental products for diagnosing, treating and preventing dental conditions. The company is headquartered in Brea, California and currently employs 12,800 full-time employees. The firm provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $705.5M ▼ | $327.6M ▼ | $38.7M ▲ | 5.49% ▲ | $0.24 ▲ | $62.5M ▼ |
| Q4-2025 | $750.6M ▲ | $337.3M ▲ | $32.9M ▲ | 4.38% ▲ | $0.2 ▲ | $104.9M ▲ |
| Q3-2025 | $669.9M ▼ | $310.3M ▼ | $-30.3M ▼ | -4.52% ▼ | $-0.18 ▼ | $94M ▲ |
| Q2-2025 | $682.1M ▲ | $319.4M ▲ | $26.4M ▲ | 3.87% ▲ | $0.16 ▲ | $80.6M ▲ |
| Q1-2025 | $616.9M | $297M | $18M | 2.92% | $0.1 | $74.6M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $1.08B ▼ | $5.58B ▼ | $2.5B ▼ | $3.08B ▼ |
| Q4-2025 | $1.21B ▲ | $5.68B ▲ | $2.57B ▲ | $3.11B ▲ |
| Q3-2025 | $1.13B ▲ | $5.64B ▼ | $2.55B ▲ | $3.09B ▼ |
| Q2-2025 | $1.11B ▲ | $5.66B ▲ | $2.53B ▲ | $3.14B ▲ |
| Q1-2025 | $1.08B | $5.47B | $2.43B | $3.04B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $38.7M ▲ | $-3.3M ▼ | $-68.9M ▼ | $-45.6M ▼ | $-128.9M ▼ | $-15.8M ▼ |
| Q4-2025 | $32.9M ▲ | $108M ▲ | $-15.5M ▼ | $-25.2M ▲ | $77.8M ▲ | $91.7M ▲ |
| Q3-2025 | $-30.3M ▼ | $78.7M ▼ | $-9.7M ▲ | $-41.7M ▲ | $23.3M ▼ | $67.9M ▼ |
| Q2-2025 | $26.4M ▲ | $88.7M ▲ | $-17.1M ▼ | $-86.4M ▼ | $33.3M ▲ | $76.4M ▲ |
| Q1-2025 | $18M | $300K | $-8.8M | $-17.6M | $8.2M | $-5.6M |
Revenue by Products
| Product | Q3-2023 | Q4-2023 | Q1-2024 | Q4-2024 |
|---|---|---|---|---|
Equipment and Consumables | $230.00M ▲ | $450.00M ▲ | $210.00M ▼ | $680.00M ▲ |
Specialty Products and Technologies | $400.00M ▲ | $830.00M ▲ | $410.00M ▼ | $1.21Bn ▲ |
Revenue by Geography
| Region | Q2-2025 | Q3-2025 | Q1-2026 |
|---|---|---|---|
North America | $350.00M ▲ | $350.00M ▲ | $360.00M ▲ |
Western Europe | $150.00M ▲ | $140.00M ▼ | $180.00M ▲ |
Q1 2026 Earnings Call Summary
Read Call Summary5-Year Trend Analysis
A comprehensive look at Envista Holdings Corp's financial evolution and strategic trajectory over the past five years.
Key strengths include a resilient and gradually growing revenue base, strong and stable gross margins, and consistently positive operating and free cash flow. The company also benefits from a broad, trusted brand portfolio, a large installed base in dental practices worldwide, and a clear strategic focus on digital and AI‑enabled solutions. Improved liquidity and reduced net debt add financial flexibility on top of these operating advantages.
Major risks center on profitability volatility and capital erosion. Significant losses and write‑downs in recent years have pushed retained earnings negative and reduced equity, even as revenue has inched higher. Rising overhead costs, intense competition in core product lines, and the need for ongoing investment in innovation all create pressure on margins and returns. Execution missteps in large initiatives—such as clear aligners or digital platforms—could further weigh on financial performance.
The overall picture is of a company with solid market positioning and cash‑generation capabilities that is working through the financial aftereffects of past charges, elevated costs, and portfolio adjustments. If Envista can stabilize margins, better align expenses with its growth pace, and successfully monetize its digital and AI investments, its financial profile could gradually move back toward the stronger levels seen earlier in the period. At the same time, the combination of competitive intensity and a still‑scarred equity base means future results may remain uneven, and progress will likely be measured more in steady operational improvements than in rapid transformation.

CEO
Paul A. Keel
Compensation Summary
(Year 2024)
Upcoming Earnings
ETFs Holding This Stock
Summary
Showing Top 3 of 196
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
Baird
Outperform
Evercore ISI Group
Outperform
JP Morgan
Neutral
Morgan Stanley
Equal Weight
Barclays
Overweight
Mizuho
Neutral
Grade Summary
Showing Top 6 of 10
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:19.62M
Value:$461.99M
BLACKROCK INC.
Shares:19.46M
Value:$458.24M
VANGUARD GROUP INC
Shares:16.38M
Value:$385.84M
Summary
Showing Top 3 of 484

